BNR — Burning Rock Biotech Income Statement
0.000.00%
- $29.09m
- -$42.25m
- CNY515.82m
- 57
- 71
- 48
- 61
Annual income statement for Burning Rock Biotech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 6-K |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 430 | 508 | 563 | 537 | 516 |
Cost of Revenue | |||||
Gross Profit | 314 | 364 | 380 | 363 | 362 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 842 | 1,305 | 1,544 | 1,207 | 873 |
Operating Profit | -412 | -797 | -980 | -669 | -358 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -407 | -796 | -969 | -651 | -341 |
Provision for Income Taxes | |||||
Net Income After Taxes | -407 | -797 | -971 | -654 | -347 |
Net Income Before Extraordinary Items | |||||
Net Income | -407 | -797 | -971 | -654 | -347 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -472 | -797 | -971 | -654 | -347 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -68.8 | -76.5 | -93.5 | -63.8 | -3.15 |